RU2016150116A - Ингибитор пролиферации раковых стволовых клеток - Google Patents
Ингибитор пролиферации раковых стволовых клеток Download PDFInfo
- Publication number
- RU2016150116A RU2016150116A RU2016150116A RU2016150116A RU2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A
- Authority
- RU
- Russia
- Prior art keywords
- stem cell
- cancer stem
- cell growth
- agonist
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 7
- 201000011510 cancer Diseases 0.000 title claims 7
- 210000000130 stem cell Anatomy 0.000 title claims 7
- 239000003112 inhibitor Substances 0.000 title claims 4
- 239000000556 agonist Substances 0.000 claims 6
- 230000010261 cell growth Effects 0.000 claims 6
- 239000003966 growth inhibitor Substances 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical group CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001973 epigenetic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
1. Ингибитор роста раковых стволовых клеток, включающий ретиноидный агонист, представляющий собой тамибаротен (Am-80) в качестве эффективного компонента.
2. Ингибитор роста раковых стволовых клеток по п. п.1, дополнительно включающий рексиноидный агонист в качестве эффективного компонента.
3. Ингибитор роста раковых стволовых клеток по п. 2, где указанным рексиноидным агонистом является бексаротен.
4. Ингибитор роста раковых стволовых клеток по любому из пп. 1-3, включающий противораковое лекарственное средство.
5. Ингибитор роста раковых стволовых клеток по п. 4, где указанный ретиноидный агонист содержится в количестве от 0,5 до 20 мг на человеческий индивидуум; где указанный ретиноидный агонист и указанный рексиноидный агонист содержатся в общем количестве от 0,5 до 500 мг на человеческий индивидуум; и где указанное противораковое лекарственное средство содержится в количестве от 1,0 до 1000 мг на человеческий индивидуум.
6. Ингибитор роста раковых стволовых клеток по п. 4 или 5, где указанное противораковое лекарственное средство выбрано из группы, состоящей из агентов, взаимодействующих с ДНК; антиметаболитов; агентов, взаимодействующих с тубулином; молекулярно-направленных терапевтических агентов, ингибиторов эпигенетического действия, и гормонов.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014105543 | 2014-05-21 | ||
| JP2014-105543 | 2014-05-21 | ||
| PCT/JP2015/064523 WO2015178426A1 (ja) | 2014-05-21 | 2015-05-20 | がん幹細胞の増殖抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016150116A true RU2016150116A (ru) | 2018-06-22 |
| RU2016150116A3 RU2016150116A3 (ru) | 2018-09-25 |
Family
ID=54554092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150116A RU2016150116A (ru) | 2014-05-21 | 2015-05-20 | Ингибитор пролиферации раковых стволовых клеток |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170079942A1 (ru) |
| EP (1) | EP3146978B1 (ru) |
| JP (1) | JPWO2015178426A1 (ru) |
| KR (1) | KR20170005069A (ru) |
| CN (2) | CN114392252A (ru) |
| AU (1) | AU2015262349A1 (ru) |
| CA (1) | CA2949640A1 (ru) |
| ES (1) | ES2928499T3 (ru) |
| MX (1) | MX2016015092A (ru) |
| RU (1) | RU2016150116A (ru) |
| TW (1) | TW201607531A (ru) |
| WO (1) | WO2015178426A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2906800A1 (en) | 2013-03-15 | 2014-09-18 | Avisenna Cosmetics, Llc | Topical compositions for reducing the effects of aging |
| WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
| IT201800005072A1 (it) * | 2018-05-04 | 2019-11-04 | Nuovi farmaci prosenescenza | |
| RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
| RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
| WO2021261601A1 (ja) * | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| AU2022206438A1 (en) * | 2021-01-08 | 2023-07-20 | Syros Pharmaceuticals, Inc. | Treatment regimens with fixed doses of tamibarotene |
| CN114045259B (zh) * | 2021-11-08 | 2024-04-05 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009504774A (ja) * | 2005-08-18 | 2009-02-05 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにｓａｈａ及びターグレチンの併用方法 |
| EP2005954B8 (en) * | 2006-03-23 | 2012-11-28 | TMRC Co., Ltd. | Kit for cancer therapy and pharmaceutical composition for cancer therapy |
-
2015
- 2015-05-20 AU AU2015262349A patent/AU2015262349A1/en not_active Abandoned
- 2015-05-20 ES ES15796913T patent/ES2928499T3/es active Active
- 2015-05-20 MX MX2016015092A patent/MX2016015092A/es unknown
- 2015-05-20 EP EP15796913.0A patent/EP3146978B1/en active Active
- 2015-05-20 JP JP2016521132A patent/JPWO2015178426A1/ja active Pending
- 2015-05-20 KR KR1020167034364A patent/KR20170005069A/ko unknown
- 2015-05-20 CN CN202210166733.7A patent/CN114392252A/zh active Pending
- 2015-05-20 CN CN201580025982.2A patent/CN106456770A/zh active Pending
- 2015-05-20 US US15/312,484 patent/US20170079942A1/en not_active Abandoned
- 2015-05-20 CA CA2949640A patent/CA2949640A1/en not_active Abandoned
- 2015-05-20 WO PCT/JP2015/064523 patent/WO2015178426A1/ja active Application Filing
- 2015-05-20 RU RU2016150116A patent/RU2016150116A/ru not_active Application Discontinuation
- 2015-05-21 TW TW104116251A patent/TW201607531A/zh unknown
-
2019
- 2019-11-04 US US16/672,783 patent/US20200061007A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2928499T3 (es) | 2022-11-18 |
| MX2016015092A (es) | 2017-05-09 |
| AU2015262349A1 (en) | 2017-02-02 |
| EP3146978A4 (en) | 2017-12-20 |
| KR20170005069A (ko) | 2017-01-11 |
| TW201607531A (zh) | 2016-03-01 |
| RU2016150116A3 (ru) | 2018-09-25 |
| US20170079942A1 (en) | 2017-03-23 |
| US20200061007A1 (en) | 2020-02-27 |
| EP3146978A1 (en) | 2017-03-29 |
| CA2949640A1 (en) | 2015-11-26 |
| CN114392252A (zh) | 2022-04-26 |
| WO2015178426A1 (ja) | 2015-11-26 |
| EP3146978B1 (en) | 2022-07-20 |
| JPWO2015178426A1 (ja) | 2017-04-20 |
| CN106456770A (zh) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016150116A (ru) | Ингибитор пролиферации раковых стволовых клеток | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| EP3173092A3 (en) | Rna containing composition for treatment of tumor diseases | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| WO2016044189A8 (en) | Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
| EA201591792A1 (ru) | Улучшенные композиции для лечения мышечной дистрофии | |
| WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| WO2015011694A3 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| WO2015100113A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| WO2015188198A3 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
| EP3209143A4 (en) | Feeding algae to cattle at low doses to produce high omega 3 levels in beef | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| CL2015001397A1 (es) | Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad. | |
| Kwon et al. | The TRAIL Sensitization Effect of Substituted Triazolyl Curcumin Mimics Against Brain Cancer Cells. | |
| EA201692426A1 (ru) | Комбинации зальтопрофена и миорелаксанта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190218 |